000			04070nam a22004097a 4500
003			OSt
005			20240305192606.0
008			220830b |||||||| |||| 00| 0 eng d
020			_a981104466X
020			_a 9789811044663
040			_cDLC
082			_a 616.2/4 HAN
100			_a Masayuki Hanaoka _943554
222			_aadverse events agents alveolar damage DAD alveolar hemorrhage amiodarone antineoplastic ARDS associated biological DMARDs biomarkers bleomycin bronchiolitis obliterans causative drug cells checkpoint inhibitors Chest X-ray chronic clinical manifestations corticosteroid cytotoxic developed differential diagnosis diffuse alveolar damage discontinuation DLI caused DLST DMARDs dose drug-induced interstitial pneumonia drug-induced lung injury EGFR EGFR-TKIs eosinophilic pneumonia erlotinib etanercept everolimus fatal gefitinib gemcitabine grade ground glass opacity herbal medicine histopathological HRCT hypersensitivity imaging findings immune checkpoint incidence induced lung injury infection infiltration infliximab interstitial lung disease Japan Japanese patients kinase inhibitors lesions lung cancer lung toxicity lymphocytes methotrexate monoclonal antibody nivolumab nonspecific NSCLC NSIP onset organizing pneumonia pathological patients with rheumatoid pattern phase Pleural effusion pneumocytes pneumonitis protein pulmonary edema pulmonary fibrosis Pulmonary hemorrhage radiological receptor reported Respir rheumatoid arthritis risk factors shows SP-A SP-D symptoms target antineoplastic drugs therapy treatment trial tumor tyrosine kinase
245			_aDrug-Induced Lung Injury
260			_aFirst Department of Medicine Shinshu University School of Medicine Matsumoto, Nagano, Japan: _bSpringer, _cc2018
300			_a215 pages _bIncludes bibliographical references.
490			_aRespiratory Disease Series: Diagnostic Tools and Disease Managements
520			_aThis book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases. Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research.
600			_xLungs -- Wounds and injuries _943555
600			_x Drugs -- Side effects _943556
600			_x Health & Fitness -- Diseases -- General _932045
600			_xMedical -- Clinical Medicine _926816
600			_xMedical -- Diseases _928034
600			_xMedical -- Evidence-Based Medicine _932044
600			_xMedical -- Internal Medicine _926949
600			_x Drugs -- Side effects _943556
600			_xLungs -- Wounds and injuries _943555
600			_x Medicine & Public Health _942899
600			_x Pneumology/Respiratory System _943557
600			_x Medical › Pulmonary & Thoracic Medicine _924000
600			_x Medical / Clinical Medicine _926816
600			_xMedical / Pulmonary & Thoracic Medicine _926869
700			_a Hiroyuki Nakamura _943558
700			_a Kazutetsu Aoshiba _943559
942			_2ddc _cEB
999			_c9107 _d9107